✦ LIBER ✦

Rituximab is effective in the treatment of nephritis in lupus patients, refractory to conventional immunosuppressive therapy

✍ Scribed by R Martínez, A Muñoz, M L Velloso, S Rodríguez Montero…

Book ID: 120690502
Publisher: BioMed Central
Year: 2010
Tongue: English
Weight: 119 KB
Volume: 8
Category: Article
ISSN: 1479-5876
DOI: 10.1186/1479-5876-8-S1-P71

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and immunological effects of Ri

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

✍ Mónica Vigna-Perez, Berenice Hernández-Castro… 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 592 KB

Rituximab in the treatment of resistant

Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis

✍ Davies, R.; Sangle, S.; Jordan, N.; Aslam, L.; Lewis, M.; Wedgwood, R.; D'Cruz, 📂 Article 📅 2013 🏛 SAGE Publications 🌐 English ⚖ 203 KB

Is combination rituximab with cyclophosp

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

✍ Li, E. K.; Tam, L.-S.; Zhu, T. Y.; Li, M.; Kwok, C. L.; Li, T. K.; Leung, Y. Y.; 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 172 KB

Rituximab is effective in the treatment

Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis

✍ Simon R. J. Taylor; Alan D. Salama; Lavnish Joshi; Charles D. Pusey; Susan L. Li 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 2 views

Early response to immunosuppressive ther

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

✍ Frédéric A. Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## Abstract ## Objective In the Euro‐Lupus Nephritis Trial (ELNT), 90 patients with lupus nephritis were randomly assigned to a high‐dose intravenous cyclophosphamide (IV CYC) regimen (6 monthly pulses and 2 quarterly pulses with escalating doses) or a low‐dose IV CYC regimen (6 pulses of 500 mg g

Efficacy of Rituximab Combined With Wycl

Efficacy of Rituximab Combined With Wyclophosphamide in a Patient With Systemic Lupus Erythematosus and Peritoneal Vasculitis Refractory to Conventional Inmunosupressive Therapy

✍ Rocío Garrido Rasco; Francisco José García Hernández; Rocío González León; María 📂 Article 📅 2009 🏛 Elsevier Science 🌐 Spanish ⚖ 285 KB